Kazia Therapeutics Earlier Announced Its Intention To De-list From The Australian Securities Exchange
Portfolio Pulse from Charles Gross
Kazia Therapeutics Limited, an oncology-focused drug development company, has announced its intention to de-list from the Australian Securities Exchange (ASX). Post delisting, the company will maintain its listing on the NASDAQ.
October 11, 2023 | 12:40 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Kazia Therapeutics plans to de-list from the Australian Securities Exchange but will maintain its NASDAQ listing. This could potentially impact the liquidity of the stock.
The decision to de-list from ASX could potentially impact the liquidity of Kazia Therapeutics' stock. However, as the company will maintain its NASDAQ listing, US investors may not be significantly affected. The overall impact is neutral as it's unclear how this will affect the stock's performance in the short term.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100